Jiawei Li, Min Li, Jianran Guo, Dongbao Li, Yumin Yao, Wei Zhang, Chuanyou Cui, Bo Fu
{"title":"NSUN2介导SALL2 m5C甲基化抑制铁下垂并促进乳腺癌进展。","authors":"Jiawei Li, Min Li, Jianran Guo, Dongbao Li, Yumin Yao, Wei Zhang, Chuanyou Cui, Bo Fu","doi":"10.1080/15384047.2026.2695501","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Due to the heterogeneity of breast cancer (BRCA) and the limited therapeutic efficacy in specific molecular subtypes, identifying new and effective therapeutic targets remains an urgent clinical need. The transcription factor <i>SALL2</i> has been shown to play distinct roles in tumorigenesis and progression, but its specific role in BRCA remains unclear. Therefore, this study investigates the effects of <i>SALL2</i> on BRCA progression.</p><p><strong>Methods: </strong><i>SALL2</i> expression in the TCGA and clinical BRCA tissue samples was analyzed. Cell and animal models were established to validate the effects of <i>SALL2</i> on BRCA cell proliferation, migration, and tumorigenicity. Molecular experiments were performed to investigate the association between NSUN2 and SALL2 in BRCA and cellular ferroptosis regulation by SALL2.</p><p><strong>Results: </strong><i>SALL2</i> is significantly overexpressed in BRCA tissues and cell lines, knocking down <i>SALL2</i> reduces BRCA cell growth, migration, and tumorigenesis <i>in vitro</i> and <i>in vivo</i> models. The m5C methyltransferase NSUN2, together with the reader protein YBX1, modifies <i>SALL2</i> mRNA with m5C, which stabilizes the transcript. <i>SALL2</i> then acts as a transcriptional repressor by binding directly to the promoter region of <i>ACSL4</i> and inhibiting its transcriptional activity. Suppression of <i>SALL2</i> activates ferroptotic cell death by lowering the antioxidant defences of GPX4/SLC7A11 and increasing the expression of <i>ACSL4</i> and <i>COX2</i>. Ferroptosis inhibitors can reverse the growth-inhibiting effects caused by <i>SALL2</i> depletion.</p><p><strong>Conclusion: </strong>In BRCA, <i>SALL2</i> is precisely regulated by m5C RNA methylation modification, further promoting cancer progression by inhibiting cell ferroptosis, suggesting its potential as a prognostic biomarker and a target for therapy.</p>","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2695501"},"PeriodicalIF":5.7000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327353/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.\",\"authors\":\"Jiawei Li, Min Li, Jianran Guo, Dongbao Li, Yumin Yao, Wei Zhang, Chuanyou Cui, Bo Fu\",\"doi\":\"10.1080/15384047.2026.2695501\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Due to the heterogeneity of breast cancer (BRCA) and the limited therapeutic efficacy in specific molecular subtypes, identifying new and effective therapeutic targets remains an urgent clinical need. The transcription factor <i>SALL2</i> has been shown to play distinct roles in tumorigenesis and progression, but its specific role in BRCA remains unclear. Therefore, this study investigates the effects of <i>SALL2</i> on BRCA progression.</p><p><strong>Methods: </strong><i>SALL2</i> expression in the TCGA and clinical BRCA tissue samples was analyzed. Cell and animal models were established to validate the effects of <i>SALL2</i> on BRCA cell proliferation, migration, and tumorigenicity. Molecular experiments were performed to investigate the association between NSUN2 and SALL2 in BRCA and cellular ferroptosis regulation by SALL2.</p><p><strong>Results: </strong><i>SALL2</i> is significantly overexpressed in BRCA tissues and cell lines, knocking down <i>SALL2</i> reduces BRCA cell growth, migration, and tumorigenesis <i>in vitro</i> and <i>in vivo</i> models. The m5C methyltransferase NSUN2, together with the reader protein YBX1, modifies <i>SALL2</i> mRNA with m5C, which stabilizes the transcript. <i>SALL2</i> then acts as a transcriptional repressor by binding directly to the promoter region of <i>ACSL4</i> and inhibiting its transcriptional activity. Suppression of <i>SALL2</i> activates ferroptotic cell death by lowering the antioxidant defences of GPX4/SLC7A11 and increasing the expression of <i>ACSL4</i> and <i>COX2</i>. Ferroptosis inhibitors can reverse the growth-inhibiting effects caused by <i>SALL2</i> depletion.</p><p><strong>Conclusion: </strong>In BRCA, <i>SALL2</i> is precisely regulated by m5C RNA methylation modification, further promoting cancer progression by inhibiting cell ferroptosis, suggesting its potential as a prognostic biomarker and a target for therapy.</p>\",\"PeriodicalId\":9536,\"journal\":{\"name\":\"Cancer Biology & Therapy\",\"volume\":\"27 1\",\"pages\":\"2695501\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2026-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327353/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biology & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15384047.2026.2695501\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/6/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15384047.2026.2695501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.
Background: Due to the heterogeneity of breast cancer (BRCA) and the limited therapeutic efficacy in specific molecular subtypes, identifying new and effective therapeutic targets remains an urgent clinical need. The transcription factor SALL2 has been shown to play distinct roles in tumorigenesis and progression, but its specific role in BRCA remains unclear. Therefore, this study investigates the effects of SALL2 on BRCA progression.
Methods: SALL2 expression in the TCGA and clinical BRCA tissue samples was analyzed. Cell and animal models were established to validate the effects of SALL2 on BRCA cell proliferation, migration, and tumorigenicity. Molecular experiments were performed to investigate the association between NSUN2 and SALL2 in BRCA and cellular ferroptosis regulation by SALL2.
Results: SALL2 is significantly overexpressed in BRCA tissues and cell lines, knocking down SALL2 reduces BRCA cell growth, migration, and tumorigenesis in vitro and in vivo models. The m5C methyltransferase NSUN2, together with the reader protein YBX1, modifies SALL2 mRNA with m5C, which stabilizes the transcript. SALL2 then acts as a transcriptional repressor by binding directly to the promoter region of ACSL4 and inhibiting its transcriptional activity. Suppression of SALL2 activates ferroptotic cell death by lowering the antioxidant defences of GPX4/SLC7A11 and increasing the expression of ACSL4 and COX2. Ferroptosis inhibitors can reverse the growth-inhibiting effects caused by SALL2 depletion.
Conclusion: In BRCA, SALL2 is precisely regulated by m5C RNA methylation modification, further promoting cancer progression by inhibiting cell ferroptosis, suggesting its potential as a prognostic biomarker and a target for therapy.
期刊介绍:
Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.